Based on The Anatomical Therapeutic Chemical (ATC) test using GREP, the drugs almitrine and ciclopirox targeting ATP1A1 were suggested to have a potential for being repositioned for AD treatment (odds ratio (OR) = 63.0; P = 0.022 for almitrine; OR = 35.9, P = 0.035 for ciclopirox). The gene discussed is ATP1A1; the disease is Alzheimer disease.